http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
간세포암의 비수술적 치료후 생존율 평가에 의한 UICC 병기의 타당성에 관한 후향적 연구
윤종길(Jong Kil yoon),김현각(Hyun Kag Kim),이창희(Chang Hee Lee),천영국(Young Kug Cheon),김유철(You Cheoul Kim),김창민(Chang Min Kim),홍원선(Weon Seon Hong),이진오(Jhin Oh Lee),강태웅(Tae Woong Kang),최수용(Soo Yong Choi) 대한내과학회 1996 대한내과학회지 Vol.51 No.4
Objectives: The management of hepatocellular carcinoma(HCC) has been frequently complicated due to the variable hepatic dysfunction from underlying chronic liver disease. The validity of UICC staging system based on the anatomical extent of malignant lesion has been questioned because of the poor correlation between stages and clinical outcomes. The purpose of this study is to elucidate the validity of UICC staging system as a prognostic factor and to compare with Child`s classification which represents the functional status of liver. Methods: A total of 831 patients with HCC who received no specific anti-cancer treatment, TACE and/or systemic chemotherapy, between January 1988 and December 1991, were analyzed retrospectively. Factors influencing the prognosis were analyzed by Cox proportional-hazard regression model. Results: Median survival of overall HCC patients was 4 months. There was no significant difference in overall median survival between UICC stage III and IVA; but significant differences between Child A and B, Child B and C were found. UICC staging system for HCC gave less significant clinical value in predicting the survival of HCC patients regardless of the treatment modalities given. In contrast, Child`s classification was better correlated with the survival of HCC patients who received systemic chemotherapy and no specific treatment. In Cox proportional-hazard regression model, Child`s classification was the most influential prognostic factor exceeding the role of UICC system.. Conclusion: UlCC staging system is not a good system for the staging of HCC. We beIieve that the poor correlation between stages and survival originated from the neglect of hepatic dysfunction which is the major prognostic factor in HCC. It is necessary to develop a new staging system which can represent the prognosis better.
전이성 분화 갑상선암에서 200mCi 방사성 옥소 치료효과 평가를 위한 혈청 Thyroglobulin 추적검사와 전신스캔의 의의
최창운(Chang Woon Choi),임상무(Sang Moo Lim),홍성운(Sung Woon Hong),윤종길(Jong Kil Yoon),이창희(Chang Hee Lee),정상훈(Sang Hoon Jeong),권교선(Gyo Seon Kwun) 대한핵의학회 1995 핵의학 분자영상 Vol.29 No.4
N/A Thirty-eight patients with metastatic well-differentiated thyroid carcinoma treated with 200mCi 131I were false negative serum thyroglobulin values during TSH suppression or at anti-thyroglobulin antibody(+) and discrepancies between findings of whole body scan and serum thyroglobulin level. After one to five cycles of 200mCi 131I therapy, complete remission and partial were achieved at 5.3% and 57.9%, respectively. We concluded that all of serum thyroglobulin, TSH, anti-thyroglobulin antibody, 131I or 123I whole body scan were necessary in follow up of metastatic well-differentiated thyroid carcinoma. Also, if there was no response after repetitive 200mCi 131I therapy, higher doses of 131I therapy should be considered.
악성 갈색세포종 및 갑상선수질암의 131I - MIBG 을 이용한 치료
최창운(Chang Woon Choi),임상무(Sang Moo Lim),홍성운(Sung Woon Hong),윤종길(Jong Kil Yoon),류백렬(Baek Yeol Ryoo),이창희(Chang Hee Lee),정상훈(Sang Hoon Jeong),천영국(Young Kug Cheon) 대한핵의학회 1995 핵의학 분자영상 Vol.29 No.3
N/A 131I-metaiodobenzylguanidine(MIBG) has been used for the diagnosis and treatment of neural crest tumors. We report our experience with this agent in 8 patients[l multiple endocrine neoplasia(MEN) type IIb; 2 malignant pheochromocytoma; 5 medullary thyroid carcinoma(MTC)]. The therapeutic procedure consisted of 30-200 mCi of 131I-MIBG administered by slow I.V. infusion, given at 3-6 months intervals. Cummulative activity ranged from 150 mCi to 410 mCi, in 1 to 4 courses. 131I-MIBG therapy resulted in significant disease free interval in 1 malignant pheochromocytoma(no measurable lesion)after sugery; complete hormonal and tumoral response in 2 MTC(1 MEN IIb); stable disease in 1 recurred pheochromocytoma(MEN IIb); stable disease but symptomatic improvement in 1 MTC; progressive disease in 1 malignant pheochromocytoma and 2 MTC. The patients who showed progression appeared to have large inoperable tumors or postoperative remnant tumors.
전이성 또는 재발성 식도암에 대한 Cisplatin , Etoposide 및 5 - Fluorouracil ( PEF ) 복합화학요법의 치료 효과
류백렬(Baek Yeol Ryoo),임영혁(Young Hyuck Im),강윤구(Yoon Koo Kang),정상훈(Sang Hoon Jeong),김현각(Hyun Kag Kim),이창희(Chang Hee Lee),윤종길(Jong Kil Yoon),천영국(Young Kug Cheon),김서운(Seo Woon Kim),김유철(You Cheoul Kim),김창민(C 대한내과학회 1996 대한내과학회지 Vol.51 No.4
Esophageal cancer is widely disseminated in more than 80% of patients at the time of diagnosis and the prognosis of advanced esophageal cancer is dismal with a median survival of 5 to 8 months. Therefore, systemic chemotherapy has assumed an important role in the treatment of these patients. Among various combination chemotherapy regimens, the combination of cisplatin and 5-fluorouracil has been one of the most effective for esophageal cancer because of their synergism. Etoposide, although reported ineffective as a single agent, has been shown to be synergistic with cisplatin in vitro and in vivo. So, we conducted a phase 2 trial to evaluate the effect of a combination of cisplatin, etoposide and 5- FU (PEF) in patients with metastatic or recurrent esophageal cancer. Thirty-four patients with measurable lesion(s) received cisplatin (20㎎/㎡ i.v. Day 1~5), etoposide (100㎎/㎡ i.v. Day 1, 3 & 5) and 5-FU (800㎎/㎡ continuous i.v. for 12 hours, Day 1~5). Of 30 evaluable patients, 1(3.3%) had a complete response and 11(37%) had partial responses. The median duration of response was 29 weeks. The overall median survival was 34 weeks and the survival time in the responders was longer significantly than that of the non-responders. There was no significant prognostic factor influencing the response rate. Among total 135 cycles of chemotherapy, leukopenia was observed in 36% and thrombocytopenia in 4%. There was no treatment-related death. Main non-hematologic toxicities were neurotoxicity (17%), nephrotoxicity (3%), and stomatitis (10%) and diarrhea (10%). All the toxicities were mild and well tolerated. Conclusion: A combination chemotherapy of cisplatin, etoposide and 5-FU (PEF) was effective and well tolerated in patients with metastatic or recurrent esophageal cancer.